资讯

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst ...
Shares of Illumina Inc. (NASDAQ:ILMN) dropped 3.8% on Wednesday after Citi downgraded the stock from Neutral to Sell, warning ...
Illumina (ILMN) stock downgraded to Sell while Charles River (CRL) stock and Hologic (HOLX) stock were upgraded to buy at Citi. Read more here.
Investing.com -- Illumina (NASDAQ: ILMN) stock declined 3.8% Wednesday after Citi downgraded the genomic sequencing company to Sell from Neutral, citing concerns about its second-half outlook.
In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...
Novogene Europe announces the installation of its fifth Illumina NovaSeq X Plus sequencing system, expanding high-throughput ...
MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader ...
Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.
Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), Illumina Inc. (NASDAQ: ILMN) has inked a deal to absorb SomaLogic’s business ...
Illumina expects the addition of a high-margin revenue stream, although the deal is expected to close in 2026.